{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:31:24Z","timestamp":1793968284919,"version":"4.8.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jcyt.2026.102929","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T16:48:18Z","timestamp":1781542098000},"page":"102929","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A regulatory gap: addressing visible particle control in cell and gene therapies through a risk-based framework"],"prefix":"10.1016","volume":"28","author":[{"given":"Antonio","family":"Scatena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2925-5448","authenticated-orcid":false,"given":"Sarah","family":"Saietz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Stull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2026.102929_bib0001","doi-asserted-by":"crossref","unstructured":"Molina S.A., Davies S.J., Sethi D., Oh, S., Durand, N. Scott, M., et al. Particulates are everywhere, but are they harmful in cell and gene therapies? Cytotherapy 2022;24:1195\u20131200.","DOI":"10.1016\/j.jcyt.2022.07.014"},{"key":"10.1016\/j.jcyt.2026.102929_bib0002","doi-asserted-by":"crossref","first-page":"626","DOI":"10.5731\/pdajpst.2018.008615","article-title":"Conducting clinical risk assessments for visible particulate matter in parenteral preparations","volume":"72","author":"Ayres","year":"2018","journal-title":"PDA J Pharm Sci Technol"},{"key":"10.1016\/j.jcyt.2026.102929_bib0003","doi-asserted-by":"crossref","first-page":"186","DOI":"10.5731\/pdajpst.2013.00922","article-title":"Particulate matter in injectable drug products","volume":"67","author":"Langille","year":"2013","journal-title":"PDA J Pharm Sci Technol"},{"key":"10.1016\/j.jcyt.2026.102929_bib0004","article-title":"Visible particles in parenteral drug products: a review of current safety assessment practice","volume":"7","author":"Liu","year":"2024","journal-title":"Curr Res Toxicol"},{"key":"10.1016\/j.jcyt.2026.102929_bib0005","unstructured":"U.S. Food and Drug Administration. Inspection of injectable products for visible particulates: draft guidance for industry. Silver Spring, MD. Center for Drug Evaluation and Research; December 2021. Docket No. FDA-2021-D-0241. Available at https:\/\/www.fda.gov\/media\/154868\/download."},{"key":"10.1016\/j.jcyt.2026.102929_bib0006","series-title":"Sampling procedures and tables for inspection by attributes","article-title":"ANSI\/ASQ","year":"2018"},{"key":"10.1016\/j.jcyt.2026.102929_bib0007","unstructured":"International Organization for Standardization. ISO 2859-1:2026. Sampling procedures for inspection by attributes\u2014Part 1: Sampling schemes indexed by acceptance quality limit (AQL) for lot-by-lot inspection. Geneva, Switzerland: ISO; 2026."},{"key":"10.1016\/j.jcyt.2026.102929_bib0008","unstructured":"International Organization for Standardization. ISO 8536-4:2019. Infusion equipment for medical use\u2014Part 4: Infusion sets for single use, gravity feed. Geneva, Switerland: ISO; 2019."},{"key":"10.1016\/j.jcyt.2026.102929_bib0009","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1177\/1538574419861771","article-title":"Ischemic Toe Ulceration Due to Foreign Body Embolus From Hydrophilic Polymer-Coated Intravascular Device","volume":"53","author":"French","year":"2019","journal-title":"Vasc Endovasc Surg"},{"key":"10.1016\/j.jcyt.2026.102929_bib0010","unstructured":"U.S. Food and Drug Administration. Intravascular catheters, wires, and delivery systems with lubricious coatings\u2014labeling considerations: Guidance for industry and food and drug administration staff. Silver Spring, MD: Center for Devices and Radiological Health; October 2019. Docket No. FDA-2018-D-1788. Available at: https:\/\/www.fda.gov\/media\/113951\/download."},{"key":"10.1016\/j.jcyt.2026.102929_bib0011","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s13181-020-00814-3","article-title":"Pharmaceutical compounding: a history, regulatory overview, and systematic review of compounding errors","volume":"17","author":"Watson","year":"2020","journal-title":"J Med Toxicol"},{"key":"10.1016\/j.jcyt.2026.102929_bib0012","unstructured":"Alliance for Pharmacy Compounding. A snapshot of pharmacy compounding in America: 2023\u20132024. Alliance for Pharmacy Compounding; 2024. Available from: https:\/\/join.a4pc.org\/hubfs\/PDFs\/APC-Snapshot-23-24-updated-version.pdf. Accessed 2026 January"},{"key":"10.1016\/j.jcyt.2026.102929_bib0013","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2146\/sp140001","article-title":"ASHP guidelines on compounding sterile preparations","volume":"71","year":"2014","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jcyt.2026.102929_bib0014","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1164\/ajrccm.165.4.2108033","article-title":"Particulate matter contamination of intravenous antibiotics aggravates loss of functional capillary density in postischemic striated muscle","volume":"165","author":"Lehr","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcyt.2026.102929_bib0015","doi-asserted-by":"crossref","DOI":"10.1515\/pthp-2016-0004","article-title":"Particulate matter in injectable drugs: evaluation of risks to patients","author":"Perez","year":"2016","journal-title":"Pharm Technol Hosp Pharm"},{"key":"10.1016\/j.jcyt.2026.102929_bib0016","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.smim.2007.11.004","article-title":"Foreign body reaction to biomaterials","volume":"20","author":"Anderson","year":"2008","journal-title":"Semin Immunol"},{"issue":"30","key":"10.1016\/j.jcyt.2026.102929_bib0017","doi-asserted-by":"crossref","first-page":"25266","DOI":"10.1074\/jbc.M111.330902","article-title":"Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses","volume":"287","author":"Joubert","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jcyt.2026.102929_bib0018","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jcyt.2016.05.011","article-title":"Managing particulates in cell therapy: guidance for best practice","volume":"18","author":"Clarke","year":"2016","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102929_bib0019","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3109\/14653249.2012.706709","article-title":"Managing particulates in cellular therapy","volume":"14","author":"Clarke","year":"2012","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102929_bib0020","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.ymthe.2019.05.015","article-title":"Effect of cryopreservation on autologous chimeric antigen receptor T cell characteristics","volume":"27","author":"Panch","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2026.102929_bib0021","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-54462-x","article-title":"Thawed mesenchymal stem cell product shows comparable immunomodulatory potency to cultured cells in vitro and in polymicrobial septic animals","volume":"9","author":"Tan","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcyt.2026.102929_bib0022","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.reth.2023.03.006","article-title":"Reconstitution and post-thaw storage of cryopreserved human mesenchymal stromal cells: pitfalls and optimizations for clinically compatible formulants","volume":"23","author":"Aabling","year":"2023","journal-title":"Regen Ther"},{"key":"10.1016\/j.jcyt.2026.102929_bib24","doi-asserted-by":"crossref","first-page":"7714","DOI":"10.1038\/s41598-018-25602-6","article-title":"Effectiveness of in-Line Filters to completely remove particulate contamination during a pediatric multidrug infusion protocol","volume":"8","author":"Perez","year":"2018","journal-title":"Sci Rep"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S146532492600890X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S146532492600890X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:23:25Z","timestamp":1793967805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S146532492600890X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S146532492600890X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102929","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A regulatory gap: addressing visible particle control in cell and gene therapies through a risk-based framework","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102929","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Cell & Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102929"}}